2023
Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration
Koga S, Metrick M, Golbe L, Santambrogio A, Kim M, Soto-Beasley A, Walton R, Baker M, De Castro C, DeTure M, Russell D, Navia B, Sandiego C, Ross O, Vendruscolo M, Caughey B, Dickson D. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathologica Communications 2023, 11: 88. PMID: 37264457, PMCID: PMC10236843, DOI: 10.1186/s40478-023-01584-z.Peer-Reviewed Original ResearchConceptsSuperior frontal gyrusFrontal gyrusConsistent with corticobasal degenerationConsistent with progressive supranuclear palsyMotor cortexCorticobasal degenerationProgressive supranuclear palsyPosterior cortical areasPresentation of corticobasal degenerationSubtype of frontotemporal lobar degenerationRichardson's syndromeBrain regionsOccipital cortexSubcortical structuresCaudate nucleusFrontotemporal lobar degenerationTau PET scansSubstantia nigraGlobus pallidusCorticobasal syndromeGyrusSupranuclear palsyCortexCortical areasClinical presentation of progressive supranuclear palsy
2013
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Kang J, Irwin D, Chen-Plotkin A, Siderowf A, Caspell C, Coffey C, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner C, Singleton A, Toga A, Chowdhury S, Mollenhauer B, Trojanowski J, Shaw L, Lasch S, Flagg E, Poewe W, Sherer T, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Uribe L, Yankey J, Crawford K, Scutti A, Casalin P, Malferrari G, Hawkins K, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Jankovic J, Hunter C, Stern M, Darin A, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Oertel W, Willeke D, Shill H, Fernandez H, Mule J, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, McCoy A, Brooks D, Shah B, Barone P, Isaacson S, James A, Espay A, Espay K, Rowe D, Ranola M. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology 2013, 70: 1277-1287. PMID: 23979011, PMCID: PMC4034348, DOI: 10.1001/jamaneurol.2013.3861.Peer-Reviewed Original ResearchConceptsDrug-naive patientsEarly Parkinson's diseaseCSF biomarkersΒ-amyloid 1CSF Aβ1-42P-tau181Parkinson's diseaseT-tauAβ1-42Healthy controlsΑ-synucleinClinical featuresPPMI cohortParkinson's Progression Markers Initiative (PPMI) studyLower CSF Aβ1-42Early-stage Parkinson's diseaseT-tau/Aβ1Lower Aβ1-42P-tau181 concentrationsCSF t-tauΑ-synuclein levelsCerebrospinal fluid levelsCross-sectional studyEnzyme-linked immunosorbent assaySignificant correlation